Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Investor Presentation (January 2023)
37 slides from Jasper Therapeutics's investor presentation, Jan 10, 2023
Slide 1: Harnessing the Power of Jasper's Differentiated c-Kit Therapeutic Approach
Harnessing the Power of Jasper’s Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR January 2023 Exhibit 99.2
Slide 2: Safe Harbor Statements
2 Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All statements other than statements of historical fact contained in this Presentation, including statements
Slide 3: Briquilimab is an anti c-Kit antibody for multiple mast and stem cell diseases
3 Briquilimab is an anti c - Kit antibody for acute and chronic therapy in multiple mast and stem cell diseases BRIQUILIMAB (JSP191) Low to Intermediate Risk MDS (Q1 2023) Eosinophilic Esophagitis (Potential Expansion) Prurigo Nodularis (Potential Expansion) Allergic Asthma (Potential Expansion) The
Slide 4: Tyrosine kinase KIT regulates mast and stem cell survival
4 Tyrosine kinase KIT plays a central role in regulating mast and stem cell survival Mast cells play a key role in the immune system through degranulation or the release of compounds that induce inflammation Chronic Urticaria and other mast cell diseases may be the result of unregulated activation l
Slide 5: Briquilimab blocks SCF binding to c-Kit (CD117)
5 SCF c - Kit ( CD117) Briquilimab Briquilimab Blocks SCF binding to c - Kit (CD117) to directly inhibit receptor signaling Validated Mechanism of Action Briquilimab is designed to directly block SCF from binding to c - Kit (CD117) with high affinity and avidity • Aglycoslyated IgG1 antibody directl
Slide 6: Briquilimab Therapeutic Development
6 Briquilimab Therapeutic Development
Slide 7: Briquilimab for Chronic Urticaria
7 Briquilimab for Chronic Urticaria
Slide 8: Briquilimab c-Kit and mast cell activity
8 Briquilimab c - Kit and mast cell activity Activity Assay Result Binding affinity to human c - Kit Fc dimer Kd < 5 pM Biacore assessment of c - Kit signaling neutralization Ki 70pM Human mast cell c - Kit phosphorylation bioassay IC 50 1.8nM Human mast cell survival bioassay IC 50 12.5nM Monkey ma
Slide 9: Mast cell depletion in non-human primates following cutaneous wound injury
9 Briquilimab mast cell depletion in non - human primates following cutaneous wound injury Source: Amgen Internal Data
Slide 10: Briquilimab can be dosed IV or sub-cutaneous
10 Briquilimab can be dosed IV or sub - cutaneous Briquilimab IV serum concentrations Time (days) C o n c e n t r a t i o n o f J S P 1 9 1 i n S e r u m ( n g / m L ) 0 7 14 21 1 10 100 1000 10000 100000 -0001 (0.1 mg/kg) -0002 (0.1 mg/kg) -0003 (0.1 mg/kg) -0004 (0.3 mg/kg) -0006 (0.3 mg/kg) -0008
Slide 11: Phase I: Briquilimab depletes tryptase and c-Kit positive skin mast cells
11 Phase I: Briquilimab robustly depletes tryptase and c - Kit positive skin mast cells *Punch Biopsy Wound Model Source: Amgen Phase 1a (SAD = 71 Briquilimab patients; MAD = 8 Briquilimab patients) Briquilimab Phase 1a (N=71): Reduction in SCF (c - Kit) positive and Tryptase positive mast cells*
Slide 12: Celldex's barzolvolimab has demonstrated proof-of-concept of c-Kit blockade
12 Celldex’s barzolvolimab has demonstrated proof - of - concept of c - Kit signal blockade for Severe Chronic Urticaria patients Source: Celldex Late Break EAACI 2022 Presentation (June 30, 2022). Barzolvolimab Phase 1b MAD (IV) Shows Efficacy in Severe Urticaria Patients
Slide 13: Key differentiation between Briquilimab and Barzolvolimab
13 Key points of differentiation between Briquilimab and Barzolvolimab (CDX - 0159) Key Similarities Key Differences 1 c - Kit (CD117) monoclonal antibody o Both antibodies are humanized, aglycosylated IgG1 inhibitors of c - Kit signaling on mast cells 2 On - target depletion of mast cells, tryptase
Slide 14: Chronic urticaria is a significant and expanding market
14 Chronic urticaria represents a significant and expanding market, with estimated 1+ million potential patients Given Xolair’s low penetration, experts believe the antihistamine - failed market is poised for significant growth and has room for a multiple new agents CSU CIndU 2.1M per year 1M per ye
Slide 15: LR-MDS Therapeutic
THERAPEUTICS ING. LR-MDS Therapeutic
Slide 16: Briquilimab may deplete cancerous stem cells as a disease-modifying therapeutic in LR-MDS
16 Briquilimab’s Ability to Directly Deplete Cancerous Stem Cells May be Leveraged as a Disease - modifying Therapeutic in Lower - Risk MDS LR - MDS: Lower - Risk Myelodysplastic syndromes MDS HSCs Briquilimab Normal HSCs Briquilimab administered in a LR - MDS patient Shift of HSCs towards normal he
Slide 17: Depletion may enable healthy HSCs to restore functional hematopoiesis
17 Briquilimab Depletion May Enable Healthy HSCs to Take Over the Bone Marrow Niche and Restore Functional Hematopoiesis [1] Kwon et al, Blood 2019 [2] Amgen Phase I healthy volunteer data (unpublished) Briquilimab depletion and rebound of healthy HSCs 2 Reticulocytes Briquilimab lasting depletion o
Slide 18: Phase I dose-escalation study in lower-risk MDS
18 A Phase I Open - label, Dose - escalation, Safety and Tolerability Study of Briquilimab as a Second Line Therapy in Patients With Lower - risk Myelodysplastic Syndrome HI - E: Hematologic Improvement - Erythroid; Hematologic Improvement - Platelet; Hematologic Improvement - Neutrophil (IWG 2018 c
Slide 19: Briquilimab Transplant Development
19 Briquilimab Transplant Development
Slide 20: Sickle Cell & Beta Thalassemia
20 Sickle Cell & Beta Thalassemia
Slide 21: Briquilimab added to nonmyeloablative transplant for sickle cell disease
21 » Sickle cell disease (SCD) is a group of inherited red blood cell / hemoglobin disorders; patients with SCD have misshapen red blood cells, which prevents normal cell function / behavior » Patients typically develop chronic problems such as renal disease, lung disease, and pulmonary hypertension
Slide 22: SCID
6) Jasper THERAPEUTICS ING. SCID
Slide 23: Briquilimab Conditioning for Severe Combined Immunodeficiency (SCID)
23 Briquilimab Conditioning for Severe Combined Immunodeficiency (SCID) Jasper SCID Strategy: • Establish Single Agent Activity POC • Focus on Re - transplant T - B - subjects • FDA Supportive of Ultra - Orphan Data Package • Potential Priority Review Voucher
Slide 24: Durable clinical benefit in briquilimab conditioned SCID patients
24 Durable Clinical Benefit in Briquilimab Conditioned Patients With No Conditioning - Related Toxicity T - B - NK+ SCID Re - Transplant Subjects Dose Chimerism* 0.1 mg/kg + + Outcomes 0.3 mg/kg 0.6 mg/kg 1.0 mg/kg • Off IVIG, Ab response to vaccination • IVIG reduced, Chronic norovirus & URI ** res
Slide 25: SCID Phase I results: safety and tolerability
25 Briquilimab SCID Phase I Results: Safety and Tolerability to Date Clinical Safety • No briquilimab - related serious adverse events (SAEs) • No myelosuppression • No significant infusion reactions Agarwal R, et al. Clinical Immunology Society Annual Meeting (CIS); 2022 Mar 31 - Apr 3; Charlotte,
Slide 26: Potential near-term BLA and PRV opportunity in SCID
26 Potential Near - term Biologics License Application (BLA) and PRV Opportunity for Briquilimab in SCID SCID re - transplant patients are ultra orphan, high unmet need population Focus on current clinical data with briquilimab in 10 SCID re - transplant T - B - patients Generate additional supporti
Slide 27: Fanconi Anemia
OF Jasper HERAPEUTICS INC. Fanconi Anemia
Slide 28: Fanconi anemia conditioning with briquilimab at Stanford
28 Fludarabine Cyclophosphamide » Fanconi is an inherited DNA repair deficiency that leads to progressive failure of hematopoietic stem and progenitor cells and transfusion dependency » Allogeneic stem cell transplant is the only current cure, however Fanconi patients are highly susceptible to toxic
Slide 29: Potential Fanconi development path for briquilimab
29 Potential Fanconi Development Path for Briquilimab Continue to enroll under current protocol (n up to 12) Discuss path to BLA with FDA with 6 - month data in first three patients o Example: Rocket Pharmaceuticals has communicated that FDA guidance of gene therapy efficacy in at least 5 of 12 pati
Slide 30: Briquilimab Development Plan
30 Briquilimab Development Plan 2023 2024 2025 2026 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q LR - MDS LR - MDS Study n=12 - 16 LR - MDS Expansion n=40 - 50 SCID Natural History Follow - Up BLA Submission (Rolling) Urticaria IND Phase I /II MAD study n=40 Additional Sickle Cell Disease, Fancon
Slide 31: Harnessing the Power of Jasper's Differentiated c-Kit Therapeutic Approach
Harnessing the Power of Jasper’s Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR January 2023
Slide 32: Additional Slides
Additional Slides Ovesper
Slide 33: AML / MDS
THERAPEUTICS ING. AML / MDS
Slide 34: AML/MDS Study: briquilimab depletes diseased stem and progenitor cells
34 AML/MDS Study: Single Agent Briquilimab Depletes Diseased Stem & Progenitor Cells in Bone Marrow in 5 to 7 Days Stem and progenitor cell depletion following briquilimab 0.6 mg/kg single dose in AML/MDS patients Muffly L et al. Tandem Meetings Transplantation and Cellular Therapy (TCT) 2022 April
Slide 35: Briquilimab conditioning demonstrates donor cell takeover of bone marrow
35 Briquilimab Based Conditioning Demonstrates Donor Cell Takeover of Bone Marrow Stem Cells and Elimination of Detectable Cancer in Older Patients (Median donor chimerism) Clearance of detectable cancer Donor cell takeover of the bone marrow (Measurable residual disease by flow cytometry) 82% 18% B
Slide 36: No briquilimab related SAEs and proof of concept for outpatient transplant
36 No Briquilimab Related SAEs, No 100 - day Transplant Related Mortality and Proof of Concept for Outpatient Stem Cell Transplant Clinical Safety • No briquilimab related SAEs • No significant briquilimab infusion reactions • One subject with refractory late onset grade 3 acute GI GVHD • One subjec
Slide 37: 0.6 mg/kg Briquilimab Pharmacokinetics
37 0.6 mg/kg Briquilimab Pharmacokinetics: Consistent and Predictable Clearance 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 100 1000 10000 Time (days) Concentration of JSP191 in Serum (ng/mL) 3000 300 30000 Muffly L et al. Tandem Meetings Transplantation and Cellular Therapy (TCT) 2022 April 23 - 26; Salt
Jasper Therapeutics — Investor Presentation (January 2023) on 6ix